AKT1 and colorectal cancer: PIK3CA mutations (or PIK3CA amplifications [45]) may result in constitutive activation of PI3K and the downstream AKT pathway, enhancing PTGS2 activity and prostaglandin E2 synthesis and leading to inhibition of apoptosis in colorectal cancer cells [11].